Table I.
Data description | Variable | Numerical descriptions (n) | Percent (%) |
---|---|---|---|
Age | Mean | 65.9 | – |
SD | 9.4 | – | |
Gender | Male | 49 | 61.3 |
Female | 31 | 38.8 | |
Symptoms duration | Mean | 3.48 | – |
SD | 6.11 | – | |
Statins exposure | Atorvastatin | 61/71 | 85 |
Simvastatin | 7/71 | 10 | |
Rosuvastatin | 3/71 | 4 | |
Not reported | 9 | – | |
Weakness severity | Mild | 4 | 5 |
Mild-moderate | 7 | 8.8 | |
Moderate | 16 | 20 | |
Moderate-severe | 10 | 12.5 | |
Severe | 8 | 10 | |
N/A | 34 | 42.5 | |
Mild-severe | 1 | 1.3 | |
Total | 80 | 100 | |
Weakness distribution | UE + LE | 52 | 65 |
UE + LE + oropharynx | 2 | 2.5 | |
UE + neck | 1 | 1.3 | |
UE | 3 | 3.8 | |
LE | 15 | 18.8 | |
Distal extremities | 1 | 1.3 | |
Oropharynx | 1 | 1.3 | |
N/A | 5 | 6.3 | |
Total | 80 | 100 | |
Symptoms | Dysphagia | 21 | 26.3 |
Dysarthria | 1 | 1.3 | |
Dyspnea | 4 | 5 | |
Palpitation | 0 | 0 | |
Chest pain | 0 | 0 | |
Myalgia | 33 | 41.3 | |
Raynaud | 0 | 0 | |
Weight loss | 5 | 6.3 | |
Skin | 5 | 6.3 |
LE – lower extremity, N/A – not associated, SD – standard deviation, UE – upper extremity.